Ajanta Pharma


(Vaibhav1512) #662

I had asked co’s IR last yr about the impact of African currencies when Nigeria currency depreciated by around 30%. He replied that they book revenue in USD and depreciation of african currencies have no impact on Ajanta.


(Amit) #663

As per my knowledge, all global wire transaction happens on USD currency. So first domestic currency converted against USD and USD transfer to India INR. So is it correct or they are doing some hedging the currency like IT company or ?

Let me know if you have any further info about currency impact.


#664

My sense is that if they book revenues in USD, they essentially quote and receive funds in USD. In that case the only impact a weakening ZAR can have is lower purchasing power of South Africa.

The drop in Ajanta’s stock price does not surprise me much as 45-46 PE was outrageous.

I am more comfortable buying again at 25-30 PE.

The major driver of PAT growth over recent years was margin expansion which seems to have topped out. I am not saying that there may not be a 4-5% variation going forward, but margins look stabilized now compared to other pharma cos.

My thesis of investing in Ajanta is the revenue growth which looks to be compounding at 25%-30% CAGR. This alone is sufficient to make it a good investment bet at 25-30 PE.

Further margin expansion, if it were to happen, will be an icing on the cake.


(Aditya) #665

Hi Sushil,

I think a PE of 30 is quite attractive for Ajanta not only because of the 15-20% growth in profits, but also on account of the exceptionally high RoE of the company.


(Rajesh_R) #666

Any idea why Ajanta’s Dahej plant is not showing up here:

http://www.accessdata.fda.gov/scripts/cder/drls/default.cfm

I tried torrent and their recently commissioned dahej plant is listed.


(Vishnu Ch) #667

From USFDA site - http://www.fda.gov/Drugs/InformationOnDrugs/ucm135778.htm

Establishments must be registered within 5 days of beginning operations. (21 CFR 207.21(a) and 207.40 and FD&C Act sections 510©, (d), & (i)). In addition, establishments must renew registration annually between October 1st and December 31st of each year. (FD&C Act sections 510(b) & (i)).

Firms that send their initial or annual registrations during October 1st to December 31st period are considered registered until the end of following year. If a firm submits its initial, updated or annual registration outside this time frame, it is considered registered until the end of the current year and shall renew before December 31.

Most likely scenario is -
They may have registered between Oct-Dec 2015, due to which they need to renew the registration for 2016.

What we do know is the following:

  1. Unlike Torrent which had FDA Inspection on April 2015, Ajanta has not had that 1st inspection yet.
  2. But since they are sending regulatory filing batches, they would have been allotted a FEI (Facility Establishment Identifier) which would imply they may have been registered.
  3. As for Torrent, since they had started commercial operations in Nov 2015, they would have been expected to register within 5 days as stated above.

I may be wrong with my assessment and others can correct me.


Lincoln Pharma ... the next mid-cap pharma in the making ...?
(Rajesh_R) #668

Sounds like a possibility. Thanks!


(swati) #669

Hi,
I was going through the BS of ajanta pharma and observed that their fixed assets haven’t increased much in last three years . Does that mean their assets are getting old and will need to invest more in coming years

  1.    2014.       2015
    

262.73 261.4 271.32

Source: screener.in


(Rohit Ojha) #670

Ajanta gets ANDA approval for Sildenafil Citrate

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails


(Srinivasan Sundaram) #671

Torrent has only for EQ 20 mg base, but Ajanta got tentative approval for multiple strengths. does it mean Torrent has to apply again for other strengths?


(Ankit Gupta) #672

Its tentative approval and not final approval.


(Rohit Ojha) #673

Thanks for correcting @ankitgupta. I missed that


(Sandeep Patel) #674

Q3 FY16 Highlights

  • Revenue from Operations grew 16% at 473cr against Rs 408cr (YoY).
  • Profit before tax grew 13% at 152cr against 135cr (YoY).
  • PAT grew 20% at 111cr against 93cr (YoY). (Note: Relatively less Tax paid this qtr)
  • The currency devaluation and scarcity of forex availability in few emerging markets limited us to achieve our full potential.
  • Making substantial investments in R&D and manufacturing facilities to build required infrastructure to fuel growth plans.

India

  • India branded business grew 17% YoY to 128cr.
  • Total India revenue grew 1% YoY to 134cr.

Emerging Markets

  • Business grew 22% YoY to 328cr.
  • Pipeline of 1,800+ products under registration paving the way for sustained growth.

Regulated Markets

  • 7 final and 2 tentative approved ANDAs.
  • 4 products have already been launched.
  • Another 17 ANDA’s are in various stages of approval with USFDA.

R&D

  • R&D spend has increased significantly during the quarter.
  • About 5% of net sales.
  • ln 9m FY16, the total R&D expense (excluding capex) was 70cr against 41cr for the same period last year.

Manufacturing

  • Solid dosage formulation facitity at Dahej has started taking regulatory filing batches.
  • Commenced the construction of new formulation facitjty at Guwahatt with proposed investment of 300 cr and plan to operationalize it before Mar 17.

Source: http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/42F4B0CE_F18E_4562_BADC_C28039674C91_150346.pdf


(Rakesh ) #675

Thank you @lustkills for posting result details. Good thing is they are getting good traction in regulated markets.


Co has updated Investor presentation.
Here is the link
http://www.ajantapharma.com/financials/Investor_Presentation/Q3-15-16.pdf


(Rohit Kotewale) #676

Any reason for slowing growth in Domestic markets?


(Sandeep Patel) #677

Two reasons -

  1. Slowdown in key Derma brand Melacare. Management has trimmed down domestic growth expectation in Q2FY16.
  2. Moving away from low margin Domestic Institutional business (down 75% YoY to 7cr) to continue focus on Domestic Branded formulations (up 17% YoY to 128cr).

Ajanta’s USP has been knack of launching maximum number of first time launches. Of 188 actively marketed brands, 129 brands were first in India. Just need to continue this trend to get back to ~25% domestic growth.


(Srinivasan Sundaram) #678

Ajanta pharma I-sec recommendation - Target Rs 1780
Ajanta pharma ISec recommendation 03 02 2016.pdf (335.8 KB)


(Sandeep Patel) #679

“… Our target is to file more than 10 ANDAs every year and we are looking to file the products where there is a limited competition kind of scenario which are more complex and extended release, delayed release, controlled release, those kind of formulations. We are very poised to do those filings next year, particularly with the Generic Drug User Fee Amendments (GDUFA), the commitment from the FDA, to approve the ANDAs as per the predefined timeline. So, the approvals should come fast and we should be able to make those ANDA approvals, convert them into the numbers faster than before…”

  • Yogesh Agrawal (on the sidelines of the Antique Investor Conference)

Source: http://www.moneycontrol.com/news/business/planning-capexrs-300-cr-at-guwahati-plant-ajanta-pharma_5494921.html


(Rohit Ojha) #680

@hitesh2710 Please let me know if my reading of inverted head and shoulder pattern on ajanta is correct.


(Hitesh Patel) #681

pikrohit,

It is better visualised on weekly line chart.height of pattern is around rs 150. A similar pattern also is present in alembic weekly line chart though the height of the head is much smaller.